REGENERON PHARMACEUTICALS INC (REGN)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for REGN
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| REGN | Director | 68 | ["General Partner and Co‑lead of the Life Sciences team of GV (formerly Google Ventures) since 2019","Adjunct attending physician in hematology at Tufts Medical Center since 2009","Former President, Chief Executive Officer, Chair, and director of Agios Pharmaceuticals, Inc.","Former Senior Vice President, Clinical Hematology/Oncology at Genentech Inc.","Former Adjunct Clinical Professor of Medical Oncology at Stanford University School of Medicine","Former Senior Vice President of Clinical Research at Millennium Pharmaceuticals, Inc.","Former director of Foundation Medicine, Inc. and bluebird bio, Inc.","Extensive leadership experience as an executive and corporate director in the pharmaceutical and healthcare industries","Considerable research and academic experience"] | ["Compensation Committee","Technology Committee"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| AGIO | President and Chief Executive Officer | 58 | [] | [] | 2016 |
Biography sourced from the proxy statement filing.
Age: 68 Director since: 2023 Board and Committee Membership 2025 Attendance Board of Directors: 13/15 Compensation Committee: 5/5* Technology Committee: 2/2 Career Highlights General Partner and Co lead of the Life Sciences team of GV (formerly Google Ventures) since 2019 Adjunct attending physician in hematology at Tufts Medical Center since 2009 Former President, Chief Executive Officer, Chair, and director of Agios Pharmaceuticals, Inc., where he continues to serve as a strategic advisor Former Senior Vice President, Clinical Hematology/Oncology at Genentech Inc. Former Adjunct Clinical Professor of Medical Oncology at Stanford University School of Medicine Former Senior Vice President of Clinical Research at Millennium Pharmaceuticals, Inc. Former director of Foundation Medicine, Inc. and bluebird bio, Inc. Experience and Expertise Industry Experience Executive/Leadership Experience Science/Biotech Background Research/Academic Experience Business Strategy/ Operations Experience Financial Expertise Public Company CEO Experience * Dr. Schenkein was appointed as a member of the Compensation Committee of the board effective September 12, 2025. He attended all meetings of the Compensation Committee held after that date. Other Public Company Boards Denali Therapeutics Inc. Prime Medicine, Inc. Reason for Nomination Dr. Schenkein s extensive leadership experience as an executive and corporate director in the pharmaceutical and healthcare industries, as well as his considerable research and academic experience, led to the board s decision to nominate Dr. Schenkein for reelection to the board.